GeneTex
United States (US)

CDKN2A / p16INK4a recombinant protein

Cat No. GTX53844

Species Human
APPLICATION

Calculated MW

16.5 kDa. ( Note )
PROPERTIES

Form

Lyophilized powder

Buffer

PBS contains 1.0 mM DTT, pH 7.2

Storage

Reconstitute in PBS, pH 8.0 to a concentration of 0.1-1.0 mg/ml. Do not vortex. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20ºC to -80ºC

Antigen Species

Human

Expression System

E. Coli

Purity

Above 95% as determined by SDS-PAGE Analysis.

Note

For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Background

This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 cont

Research Area